Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Sunday
May 08
08:45 - 10:00
Room D2
Image guidance in particle therapy: Status and outlook
Kathrine Røe Redalen, Norway;
Petra Trnkova, Austria
Symposium
Physics
09:39 - 09:57
Towards MR integration in particle therapy
Aswin Hoffmann, Germany
SP-0369

Abstract

Towards MR integration in particle therapy
Authors:

Aswin Hoffmann1

1OncoRay – National Center for Radiation Research in Oncology, Medical Radiation Physics, Dresden, Germany

Show Affiliations
Abstract Text

Image guidance plays an undisputed pivotal role in modern radiation therapy to achieve high local control rates and keep side-effects within tolerable levels. Technological developments in on-board imaging for photon beam therapy have enabled daily treatment adaptation for anatomical changes that occur in between or during treatment fractions. The rapid adoption of real-time MR-LINAC systems since its clinical introduction in 2014 has enabled online adaptive treatment workflows based on high soft-tissue contrast magnetic resonance imaging (MRI), allowing dose distributions to be tailored and delivered to the individual patient’s changing anatomy with a high targeting precision.
The lack of fast, high soft-tissue contrast image-guidance in particle therapy is considered a major hindrance for exploiting its full potential to outperform image-guided photon therapy for soft-tissue tumors in general, and those that are subject to motion in particular. The successful clinical introduction of the MR-LINAC systems triggered the particle therapy community to consider the feasibility of MRI guidance for particle therapy. Different scenarios for that include near-room, in-room, and in-beam MRI. An overview of potential clinical indications for these scenarios is presented and discussed. Whereas near-room and in-room MRI may account for interfractional changes and enable offline and online adaptive treatments, respectively, but require post-imaging patient repositioning and do not account for intrafractional changes, in-beam MRI would facilitate imaging in treatment position, both prior to and during dose delivery. The latter real-time approach will improve the targeting precision for moving soft-tissue tumors, which represent a large proportion of clinical cases treated with particle therapy. The added value of MRI-integration in particle therapy is hence expected to be even more favorable than in photon therapy.
However, the full integration of real-time MRI and particle therapy presents a plethora of technical challenges, starting from scanner integration with the beam line, through dosimetry and treatment planning in the presence of the MR magnetic fields, MR-only based treatment planning, online treatment adaptation and quality assurance, up to online MRI-based range verification.
This contribution provides an overview of recent developments and milestones achieved by various groups on the aforementioned topics. A roadmap for the clinical introduction of in-beam MR-integrated proton therapy is presented, showing ongoing research efforts to address the knowledge gaps and remaining challenges to be solved before a first patient can be safely treated with particle therapy inside an in-beam MRI device. These include artifact-free imaging during irradiation, workflow development, and comparative treatment planning studies demonstrating the expected clinical benefit of real-time in-beam MR-integrated particle therapy over CBCT-guided particle therapy, offline MR-guided particle therapy and MR-LINAC treatments for relevant indications in the thorax, abdomen and pelvis.